Atrium Therapeutics, Inc. (RNA) Stock Forecast
Data as of May 10, 2026Healthcare · Current price $13.10 (+1.04%)
Consensus Target
—
Upside
—
Analysts
1
Rating
Hold(3.00)
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
6-Month Trend
No rating trend data.
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
No analyst price targets available.
RNA vs Sector & Market
| Metric | RNA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.24 | 2.41 |
| Analyst Count | 1 | 8 | 19 |
| Target Upside | — | +1708.8% | +16.4% |
| P/E Ratio | -2.80 | 3.30 | 27.60 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $3M | $3M | $3M | 1 |
| 2026-09-30 | $5M | $5M | $5M | 1 |
| 2026-12-31 | $11M | $11M | $11M | 1 |
| 2027-12-31 | $149M | $288M | $438M | 4 |
| 2028-12-31 | $876M | $913M | $950M | 7 |
| 2029-12-31 | $862M | $1.61B | $2.54B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-1.51 | $-1.29 | $-1.02 | 2 |
| 2026-09-30 | $-1.34 | $-1.34 | $-1.34 | 1 |
| 2026-12-31 | $-1.34 | $-1.34 | $-1.34 | 1 |
| 2027-12-31 | $-4.05 | $-4.01 | $-3.95 | 3 |
| 2028-12-31 | $-4.48 | $-1.82 | $1.96 | 6 |
| 2029-12-31 | $0.73 | $1.83 | $3.21 | 4 |
Frequently Asked Questions
What is the analyst consensus for RNA?
The consensus among 1 analysts covering Atrium Therapeutics, Inc. (RNA) is Hold with an average price target of N/A.
How many analysts cover RNA?
1 analysts have issued ratings for Atrium Therapeutics, Inc. in the past 12 months.
Is RNA a buy or sell right now?
Based on 1 analyst ratings, RNA has a consensus rating of Hold (3.00/5) with a N/A upside to the consensus target of N/A.
What are the earnings estimates for RNA?
Analysts estimate RNA will report EPS of $-1.29 for the period ending 2026-06-30, with revenue estimated at $3M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.